A systematic review of the literature from 1992 through 2004 to identify relevant
randomized controlled trials and cost-effectiveness studies was completed in 2005. Clinically
preventable burden (CPB) was calculated as the product of effectiveness times the
alcohol-attributable fraction of both mortality and morbidity (measured in quality-adjusted
life years or QALYs), for all relevant conditions. Cost effectiveness from both the societal
perspective and the health-system perspective was estimated. These analyses were completed
in 2006.